The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Single-agent activity of the anti-GD2 antibody dinutuximab beta given as a long-term infusion in relapsed and refractory neuroblastoma (APN311-304).
 
Holger N. Lode
Honoraria - EUSA Pharma
Consulting or Advisory Role - EUSA Pharma
Research Funding - EUSA Pharma (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - EUSA Pharma
 
Karoline Ehlert
No Relationships to Disclose
 
Stephanie Huber
No Relationships to Disclose
 
Nikolai Siebert
No Relationships to Disclose
 
Sascha Troschke-Meurer
No Relationships to Disclose
 
Maxi Zumpe
No Relationships to Disclose
 
Hans Loibner
Stock and Other Ownership Interests - Apeiron Biologics
Patents, Royalties, Other Intellectual Property - Apeiron Biologics
(OPTIONAL) Uncompensated Relationships - JLP Health
 
Ruth Lydia Ladenstein
Consulting or Advisory Role - Apeiron Biologics; Boehringer Ingelheim; EUSA Pharma (Inst)
Research Funding - Apeiron Biologics (Inst); EUSA Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Apeiron Biologics (Inst); EUSA Pharma (Inst)
Expert Testimony - Apeiron Biologics; EUSA Pharma